The first in-human Clinical Phase I study of intratumoural tigilanol tiglate has been published in The Lancet's EBioMedicine journal

10 December 2019 An efficacious dose was achieved and a Maximum Tolerated Dose (MTD) was not reached, indicating tigilanol tiglate tolerability in humans. Promising outcomes were attained in patients with a variety of solid tumour types, with a 27% treatment response, including 18% complete response (full tumour destruction). Following these positive results, a Phase I/II trial of tigilanol tiglate in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) is underway, with the first patient successfully dosed. Read the full news release

The release as fetched from its publisher. qbiotics.com ↗